European Journal of Dermatology

, Volume 26, Issue 5, pp 506–507 | Cite as

Exacerbation of depression in a psoriatic arthritis patient possibly induced by secukinumab

  • Takaya Komori
  • Atsushi Otsuka
  • Yuki Honda
  • Shuto Kanameishi
  • Tetsuya Honda
  • Kenji Kabashima


  1. 1.
    Honda Y, Otsuka A, Egawa G, et al. Multiple neurological abnormalities, including pontine hemorrhage, multiple sclerosis and aseptic meningitis, during anti-TNF-β therapy in psoriatic arthritis. Eur J Dermatol 2015; 25: 487–8.PubMedGoogle Scholar
  2. 2.
    Novartis pharmaceuticals corporation: Highlights of prescribing information: Cosentyx homepage;2014. Available at: 8 Apr 2016).Google Scholar
  3. 3.
    Waisman A, Hauptmann J, Regen T. The role of IL-17 in CNS diseases. Acta Neuropathol 2015; 129: 625–37.CrossRefPubMedGoogle Scholar
  4. 4.
    Liu Y, Ho RC, Mak A. The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis. Int J Rheum Dis 2012; 15: 183–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891–5.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler 2003; 9: 540–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Danesh MJ, Kimball AB. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J Am Acad Dermatol 2016; 74: 190–2.CrossRefPubMedGoogle Scholar
  8. 8.
    Celgene corporation: Otezla prescribing information: Otezla homepage; 2015. Available at: 12 May 2016).Google Scholar

Copyright information

© John Libbey Eurotext 2016

Authors and Affiliations

  1. 1.Department of DermatologyKyoto University Graduate School of MedicineKyotoJapan

Personalised recommendations